Allogene Therapeutics announced Tuesday morning that it intends to assume Pfizer's (PFE) global strategic collaboration with Cellectis (CLLS) for the development of "off-the-shelf" CAR T immunotherapies for oncology.
from RTT - Before the Bell https://ift.tt/2JficBA
via IFTTT
No comments:
Post a Comment